Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
Charlie Blackie-Kelly | October 6, 2025 | News story | Research and Development | Bio-Rad, Diagnostics and Testing, Gencurix, oncology
Bio-Rad Laboratories, a global provider of research and clinical diagnostic products, has entered into a strategic agreement with Gencurix, a South Korea-based developer of oncology testing solutions. Under the deal, Bio-Rad becomes the exclusive distributor of Gencurix’s digital oncology testing kits in Europe.
The partnership builds on the companies’ existing collaboration. Gencurix’s in vitro diagnostic assays, which utilise droplet digital PCR technology, are designed for use with Bio-Rad’s systems and incorporate the company’s proprietary platform.
“This partnership will provide clinical laboratories with access to highly sensitive and reliable molecular tools, supporting compliance while ensuring the highest standards of diagnostic accuracy,” said Steve Kulisch, vice president, Product Management, Digital Biology Group, Bio-Rad Laboratories.
The assays are designed to detect clinically relevant mutations in several major cancer types, including melanoma, colorectal cancer, and non-small cell lung cancer.
Under the terms of the agreement, Bio-Rad will leverage its established European commercial network and clinical diagnostics infrastructure to distribute the Gencurix kits. The deal also provides for joint marketing initiatives, product development collaboration, and expanded commercialisation opportunities across the region.
“This partnership will accelerate access to our innovative diagnostic tools for oncology applications throughout Europe, supporting improved patient outcomes through precision medicine,” commented Sang Rae Cho, CEO of Gencurix.
Related Content
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
Micrima announces upcoming launch of new UK breast cancer assessment
Breast cancer remains one of the leading health threats to women over 35 in the …
